India’s biotechnology industry, one of the fastest-expanding sectors globally, is blazing new trails across healthcare, pharmaceuticals, and sustainability.

Motilal Oswal Financial Services has reiterated its BUY call on Laurus Labs, highlighting a robust earnings trajectory and strategic capital deployment in CDMO and generics segments.

Costco’s decision to introduce discounted pricing on Ozempic and Wegovy marks a pivotal moment in both the U.S.

Motilal Oswal Financial Services has suggested BUY recommendation for Sun Pharmaceutical, targeting a 12-month price of Rs 1,960.

Prabhudas Lilladher has initiated a BUY call on Ajanta Pharma, urging investors to seize this opportunity based on the company’s robust branded generics (BGx) franchise, promising financial perform

Geojit Investments has issued an Accumulate rating on Granules India Limited, maintaining a revised target price of Rs 630, reflecting a potential upside of around 16% from the cur